Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Sell
20
PRTC Quote, Financials, Valuation and Earnings
Last price:
$18.87
Seasonality move
:
-6.06%
Day range:
$18.80 - $18.80
52-week range:
$18.19 - $34.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
300.98x
P/B ratio:
1.43x
Volume:
351
Avg. volume:
4.8K
1-year change:
-24.8%
Market cap:
$450.1M
Revenue:
$750K
EPS (TTM):
-$3.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRTC
PureTech Health PLC
|
-- | -- | -- | -- | $53.25 |
|
EWTX
Edgewise Therapeutics
|
-- | -$0.42 | -- | -15.68% | $49.14 |
|
IBIO
iBio
|
-- | -$0.45 | -100% | -89.82% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$2.5M | -$0.24 | -60.77% | -99.16% | $7.30 |
|
PTN
Palatin Technologies
|
-- | -$0.42 | -100% | -25% | -- |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRTC
PureTech Health PLC
|
$18.80 | $53.25 | $450.1M | -- | $0.00 | 0% | 300.98x |
|
EWTX
Edgewise Therapeutics
|
$27.72 | $49.14 | $2.6B | -- | $0.00 | 0% | -- |
|
IBIO
iBio
|
$2.45 | -- | $22.4M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.62 | $7.30 | $3M | -- | $0.00 | 0% | 0.07x |
|
PTN
Palatin Technologies
|
$1.37 | -- | $26.8M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.59 | -- | $4.4M | -- | $0.00 | 0% | 1.59x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRTC
PureTech Health PLC
|
-- | 1.607 | -- | -- |
|
EWTX
Edgewise Therapeutics
|
-- | -0.033 | -- | -- |
|
IBIO
iBio
|
4.41% | 8.236 | 5.41% | 3.89x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.365 | 1.51% | 0.75x |
|
PTN
Palatin Technologies
|
-- | -3.016 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.870 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRTC
PureTech Health PLC
|
-- | -- | -- | -- | -- | -- |
|
EWTX
Edgewise Therapeutics
|
-- | -$40.4M | -- | -- | -- | -$27.9M |
|
IBIO
iBio
|
-- | -$4.1M | -90.99% | -148.3% | -1820.57% | -$3.7M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
PTN
Palatin Technologies
|
$350K | -$7.8M | -- | -- | -2356.3% | -$7M |
|
TOVX
Theriva Biologics
|
-- | -$5M | -- | -- | -- | -$3.9M |
PureTech Health PLC vs. Competitors
-
Which has Higher Returns PRTC or EWTX?
Edgewise Therapeutics has a net margin of -- compared to PureTech Health PLC's net margin of --. PureTech Health PLC's return on equity of -- beat Edgewise Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRTCPureTech Health PLC-- -- -- EWTXEdgewise Therapeutics-- -$0.36 -- -
What do Analysts Say About PRTC or EWTX?
PureTech Health PLC has a consensus price target of $53.25, signalling upside risk potential of 183.25%. On the other hand Edgewise Therapeutics has an analysts' consensus of $49.14 which suggests that it could grow by 78.31%. Given that PureTech Health PLC has higher upside potential than Edgewise Therapeutics, analysts believe PureTech Health PLC is more attractive than Edgewise Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings PRTCPureTech Health PLC2 0 0 EWTXEdgewise Therapeutics4 0 0 -
Is PRTC or EWTX More Risky?
PureTech Health PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRTC or EWTX?
PureTech Health PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PureTech Health PLC pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTC or EWTX?
PureTech Health PLC quarterly revenues are --, which are smaller than Edgewise Therapeutics quarterly revenues of --. PureTech Health PLC's net income of -- is lower than Edgewise Therapeutics's net income of -$34.1M. Notably, PureTech Health PLC's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PureTech Health PLC is 300.98x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTCPureTech Health PLC300.98x -- -- -- EWTXEdgewise Therapeutics-- -- -- -$34.1M
-
Which has Higher Returns PRTC or IBIO?
iBio has a net margin of -- compared to PureTech Health PLC's net margin of -4444.57%. PureTech Health PLC's return on equity of -- beat iBio's return on equity of -148.3%.
Company Gross Margin Earnings Per Share Invested Capital PRTCPureTech Health PLC-- -- -- IBIOiBio-- -$0.46 $22.3M -
What do Analysts Say About PRTC or IBIO?
PureTech Health PLC has a consensus price target of $53.25, signalling upside risk potential of 183.25%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 46.94%. Given that PureTech Health PLC has higher upside potential than iBio, analysts believe PureTech Health PLC is more attractive than iBio.
Company Buy Ratings Hold Ratings Sell Ratings PRTCPureTech Health PLC2 0 0 IBIOiBio0 0 0 -
Is PRTC or IBIO More Risky?
PureTech Health PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iBio has a beta of -3.266, suggesting its less volatile than the S&P 500 by 426.584%.
-
Which is a Better Dividend Stock PRTC or IBIO?
PureTech Health PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PureTech Health PLC pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTC or IBIO?
PureTech Health PLC quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. PureTech Health PLC's net income of -- is lower than iBio's net income of -$4M. Notably, PureTech Health PLC's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PureTech Health PLC is 300.98x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTCPureTech Health PLC300.98x -- -- -- IBIOiBio-- -- $175K -$4M
-
Which has Higher Returns PRTC or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to PureTech Health PLC's net margin of -49.65%. PureTech Health PLC's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital PRTCPureTech Health PLC-- -- -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About PRTC or NBY?
PureTech Health PLC has a consensus price target of $53.25, signalling upside risk potential of 183.25%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 503.14%. Given that NovaBay Pharmaceuticals has higher upside potential than PureTech Health PLC, analysts believe NovaBay Pharmaceuticals is more attractive than PureTech Health PLC.
Company Buy Ratings Hold Ratings Sell Ratings PRTCPureTech Health PLC2 0 0 NBYNovaBay Pharmaceuticals2 0 0 -
Is PRTC or NBY More Risky?
PureTech Health PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.
-
Which is a Better Dividend Stock PRTC or NBY?
PureTech Health PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PureTech Health PLC pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTC or NBY?
PureTech Health PLC quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. PureTech Health PLC's net income of -- is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, PureTech Health PLC's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PureTech Health PLC is 300.98x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTCPureTech Health PLC300.98x -- -- -- NBYNovaBay Pharmaceuticals0.07x -- $2.4M -$1.2M
-
Which has Higher Returns PRTC or PTN?
Palatin Technologies has a net margin of -- compared to PureTech Health PLC's net margin of -2357.27%. PureTech Health PLC's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRTCPureTech Health PLC-- -- -- PTNPalatin Technologies-- -$0.39 -$111.5K -
What do Analysts Say About PRTC or PTN?
PureTech Health PLC has a consensus price target of $53.25, signalling upside risk potential of 183.25%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1140.88%. Given that Palatin Technologies has higher upside potential than PureTech Health PLC, analysts believe Palatin Technologies is more attractive than PureTech Health PLC.
Company Buy Ratings Hold Ratings Sell Ratings PRTCPureTech Health PLC2 0 0 PTNPalatin Technologies0 0 0 -
Is PRTC or PTN More Risky?
PureTech Health PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.
-
Which is a Better Dividend Stock PRTC or PTN?
PureTech Health PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PureTech Health PLC pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTC or PTN?
PureTech Health PLC quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. PureTech Health PLC's net income of -- is lower than Palatin Technologies's net income of -$7.8M. Notably, PureTech Health PLC's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PureTech Health PLC is 300.98x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTCPureTech Health PLC300.98x -- -- -- PTNPalatin Technologies-- -- $350K -$7.8M
-
Which has Higher Returns PRTC or TOVX?
Theriva Biologics has a net margin of -- compared to PureTech Health PLC's net margin of --. PureTech Health PLC's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRTCPureTech Health PLC-- -- -- TOVXTheriva Biologics-- -$6.81 -- -
What do Analysts Say About PRTC or TOVX?
PureTech Health PLC has a consensus price target of $53.25, signalling upside risk potential of 183.25%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 5591.82%. Given that Theriva Biologics has higher upside potential than PureTech Health PLC, analysts believe Theriva Biologics is more attractive than PureTech Health PLC.
Company Buy Ratings Hold Ratings Sell Ratings PRTCPureTech Health PLC2 0 0 TOVXTheriva Biologics0 0 0 -
Is PRTC or TOVX More Risky?
PureTech Health PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.
-
Which is a Better Dividend Stock PRTC or TOVX?
PureTech Health PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PureTech Health PLC pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTC or TOVX?
PureTech Health PLC quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. PureTech Health PLC's net income of -- is lower than Theriva Biologics's net income of -$7.7M. Notably, PureTech Health PLC's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PureTech Health PLC is 300.98x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTCPureTech Health PLC300.98x -- -- -- TOVXTheriva Biologics1.59x -- -- -$7.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Why Buy Domino’s Pizza Stock?
When you think of growth stocks, you probably imagine technology…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
70
OKLO alert for Jan 6
Oklo [OKLO] is up 10.09% over the past day.
Sell
39
DOGZ alert for Jan 6
Dogness (International) [DOGZ] is up 3.39% over the past day.
Buy
66
DMRC alert for Jan 6
Digimarc [DMRC] is up 1.05% over the past day.
